Rezdiffra (Resmetirom) Cognitive Function Impact: What the Clinical Evidence Shows

What Is Resmetirom and Why Does Cognition Matter?

Resmetirom is the first drug approved specifically for MASH with moderate-to-advanced liver fibrosis (F2 or F3). Cognitive health is a relevant concern because MASH frequently co-occurs with metabolic syndrome, obesity, and type 2 diabetes, all of which carry independent risk for cognitive decline. Understanding whether a new hepatic drug adds to or subtracts from that risk matters clinically.

The MASH-Cognition Connection

MASH does not exist in isolation. Patients with MASH carry a substantially higher burden of insulin resistance, dyslipidemia, and systemic inflammation, all of which have been associated with accelerated cognitive aging [1]. A 2022 analysis in JAMA Neurology found that non-alcoholic fatty liver disease (NAFLD) is linked to a 23% increased risk of dementia compared with age-matched controls [2]. That background risk makes any new MASH therapy's cognitive profile worth examining carefully.

Why the Thyroid Receptor Biology Matters

Thyroid hormones regulate neuronal differentiation, myelination, and synaptic plasticity primarily through thyroid hormone receptor alpha (THR-alpha) in the brain [3]. Resmetirom is engineered to bind THR-beta with high selectivity. THR-beta predominates in the liver, where it governs lipid metabolism and fatty acid oxidation. The liver-over-brain selectivity ratio for resmetirom is estimated at roughly 10:1 based on receptor-binding pharmacology data reviewed in the FDA briefing document [4]. That ratio means the CNS sees far less pharmacologically active drug relative to hepatic tissue.

How Resmetirom Works: Mechanism and Selectivity

Resmetirom activates THR-beta in hepatocytes, which increases mitochondrial fatty acid beta-oxidation, reduces de novo lipogenesis, and lowers LDL-cholesterol by upregulating LDL receptor expression [5]. These are the same pathways thyroid hormone itself would activate, but resmetirom achieves this without the tachycardia, bone loss, or anxiogenic effects that a non-selective thyroid hormone mimetic would cause.

Receptor Selectivity Profile

THR-beta selectivity over THR-alpha for resmetirom is approximately 28-fold in binding assays, according to the preclinical pharmacology data submitted to the FDA [4]. This selectivity is meaningful for the brain because:

• THR-alpha mediates most of the thyroid hormone effects on cardiac rate and CNS excitability.
• THR-beta is expressed at lower levels in the brain relative to the liver.
• Hepatic first-pass extraction concentrates resmetirom in the liver before systemic distribution.

The net result is that CNS exposure remains low, and the receptor population most relevant to neurological function (THR-alpha) is largely unaffected at therapeutic doses [4].

What Selectivity Does Not Guarantee

Selectivity does not equal zero brain exposure. Some THR-beta is expressed in the hypothalamus and pituitary, where it participates in thyroid-stimulating hormone (TSH) regulation [3]. In MAESTRO-NASH, TSH levels decreased modestly but remained within the normal reference range at both the 80 mg and 100 mg doses [6]. A TSH that stays normal is a reasonable surrogate marker that the drug is not triggering systemic hyperthyroidism, which itself would be the most direct pharmacological route to cognitive disruption.

MAESTRO-NASH Trial: Cognitive Safety Data

MAESTRO-NASH enrolled 966 adults with biopsy-confirmed MASH and fibrosis stage F1B, F2, or F3 [6]. Participants were randomized 1:1:1 to resmetirom 80 mg, resmetirom 100 mg, or placebo once daily for 52 weeks. The primary endpoints were NASH resolution without worsening fibrosis, and fibrosis improvement by at least one stage without worsening NASH activity.

Primary Efficacy Results

The trial results, published in the New England Journal of Medicine in March 2024, showed:

• NASH resolution: 29.9% (80 mg) and 37.9% (100 mg) vs. 9.7% placebo (P<0.001 for both doses) [6].
• Fibrosis improvement: 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo (P<0.001) [6].

These are the largest histological response rates recorded in a phase 3 MASH trial to date.

Cognitive Adverse Events: The Reported Signal

The published MAESTRO-NASH safety table does not list cognitive impairment, memory disturbance, or psychiatric adverse events among the treatment-emergent events occurring at a frequency that exceeded placebo by a clinically meaningful margin [6]. Nausea and diarrhea were the most common adverse events, each occurring in roughly 25-33% of participants on active drug vs. Approximately 14% on placebo. No seizures, encephalopathic episodes, or dementia-related terms appeared in the reported adverse event listings.

This absence of a cognitive signal is consistent with the receptor-selectivity argument above. The trial was not designed with formal neuropsychological testing as an endpoint, so the data cannot definitively rule out subtle cognitive effects. What it can say is that no detectable signal emerged across 966 participants over 52 weeks.

Hepatic Encephalopathy Considerations

Patients with advanced MASH occasionally develop hepatic encephalopathy (HE) as their liver disease progresses. HE itself causes cognitive impairment through ammonia accumulation and neuroinflammation [7]. MAESTRO-NASH enrolled patients with F1B-F3 fibrosis, not cirrhosis (F4), so the trial population was not at high risk for HE at baseline. Whether resmetirom could reduce HE incidence by slowing fibrosis progression is an open research question that longitudinal extension data may address.

Indirect Cognitive Effects: Lipids, Inflammation, and Insulin

Even if resmetirom has no direct CNS pharmacology worth worrying about, its systemic metabolic effects could influence cognition indirectly.

LDL Reduction and Cerebrovascular Risk

In MAESTRO-NASH, the 100 mg dose reduced LDL-cholesterol by a mean of 26.6% from baseline at week 24 [6]. Elevated LDL is an established risk factor for atherosclerotic cardiovascular disease, and cerebrovascular disease is a leading contributor to vascular cognitive impairment [8]. A drug that lowers LDL by roughly one-quarter could, over years, reduce the burden of small-vessel cerebrovascular disease in a population already at elevated cardiovascular risk.

The American Heart Association's 2023 guideline on cardiovascular risk reduction notes that each 1 mmol/L reduction in LDL reduces major cardiovascular events by approximately 22% [8]. Whether that cardiovascular benefit translates into measurable cognitive protection over the 5-to-10-year time horizon relevant to dementia risk has not been tested for resmetirom specifically.

Systemic Inflammation

MASH is characterized by hepatic and systemic inflammation driven by TNF-alpha, IL-6, and other cytokines [9]. Neuroinflammation, partly mediated by systemic cytokines crossing or signaling across the blood-brain barrier, has been implicated in multiple cognitive disorders including Alzheimer disease [10]. Resmetirom's ability to reduce hepatic steatosis and lobular inflammation (as confirmed histologically in MAESTRO-NASH) may secondarily reduce the systemic cytokine load. Whether this translates to measurable neuroinflammation reduction has not been tested in human imaging or CSF studies for this drug.

Insulin Sensitivity

Resmetirom improved markers of insulin resistance in MAESTRO-NASH participants, consistent with its mechanism of increasing hepatic fatty acid oxidation and reducing ectopic lipid accumulation [6]. Insulin resistance in the brain impairs glucose uptake in neurons, and brain insulin signaling plays a role in memory consolidation and hippocampal function [11]. Improving peripheral insulin sensitivity does not automatically normalize brain insulin signaling, but the two are not entirely disconnected either.

Pharmacokinetics: Why the Brain Sees Less Drug

Understanding the pharmacokinetics of resmetirom helps explain why CNS effects are limited.

Hepatic First-Pass Extraction

Resmetirom is absorbed from the gut and undergoes substantial hepatic first-pass uptake via organic anion transporting polypeptides (OATPs), particularly OATP1B1 and OATP1B3 [4]. These transporters concentrate the drug in hepatocytes before it reaches systemic circulation. Peak plasma concentration (Cmax) is therefore a fraction of what would be predicted from dose alone. The drug's high protein binding (greater than 99%) further limits free drug available for CNS penetration [4].

Blood-Brain Barrier Penetration

Resmetirom has a high molecular weight relative to CNS-penetrant small molecules, and its protein binding leaves minimal free drug to cross the blood-brain barrier. No dedicated CNS pharmacokinetic study has been published, but the combination of hepatic extraction and protein binding creates a pharmacokinetic argument consistent with the receptor-selectivity argument for low CNS activity [4].

Half-Life and Steady State

The elimination half-life of resmetirom is approximately 10 hours, with steady-state plasma concentrations reached within 7 days of once-daily dosing [4]. This relatively short half-life means no unusual drug accumulation should occur in tissues, including brain, over prolonged use.

Thyroid Hormone and Cognition: The Background Science

To assess resmetirom's cognitive risk profile correctly, the relationship between thyroid function and cognition must be understood.

Overt Hypothyroidism

Overt hypothyroidism produces cognitive slowing, memory impairment, and in severe cases myxedema coma [3]. Patients with MASH who have co-existing untreated hypothyroidism carry dual metabolic and cognitive risk. Resmetirom does not treat hypothyroidism, and its TSH-lowering effect at therapeutic doses is modest and non-suppressive [6]. Clinicians should still screen MASH patients for thyroid dysfunction before initiating resmetirom, as per standard metabolic workup.

Subclinical Hyperthyroidism

Subclinical hyperthyroidism (low TSH, normal free T4) has been associated with atrial fibrillation and, in some studies, a small increase in dementia risk in older adults [12]. Because resmetirom acts via THR-beta and not through the pituitary's THR-beta-mediated TSH suppression pathway in a clinically meaningful way at approved doses, the drug is not expected to cause the sustained TSH suppression seen with exogenous thyroid hormone overdose. MAESTRO-NASH data confirm TSH remained within normal limits [6].

THR-Alpha in the Developing Brain

THR-alpha is essential for fetal and neonatal brain development [3]. Resmetirom carries a Pregnancy Category warning and is not indicated in pediatric patients. The question of THR-alpha impact on cognition is clinically relevant primarily during development, not in the adult MASH population, which is the approved indication.

Practical Guidance for Clinicians

The following framework summarizes how to approach cognitive monitoring in patients starting resmetirom:

Pre-Treatment Baseline Assessment

1. Obtain TSH, free T4, and free T3 before starting resmetirom. Correct any thyroid dysfunction first.
2. Screen for baseline cognitive concerns using a validated brief instrument such as the Montreal Cognitive Assessment (MoCA) in patients over 60 or those with significant metabolic syndrome burden.
3. Review the medication list for drugs that could independently affect cognition (benzodiazepines, anticholinergics, opioids) and optimize where possible.
4. Document lipid panel (LDL, HDL, triglycerides) as a cardiovascular and indirect-cognitive-risk baseline.

Monitoring During Treatment

• Recheck TSH at 4-to-8 weeks after starting resmetirom and every 6 months thereafter. A TSH below the lower limit of normal warrants dose review.
• Recheck LDL at 12 weeks. A reduction of 20-30% from baseline is consistent with expected drug effect.
• Ask specifically about new or worsening cognitive symptoms at each visit. Patients often do not volunteer these complaints.

When to Refer

Any patient who develops new confusion, memory loss, or personality change on resmetirom should be evaluated for:

• Hepatic encephalopathy (check ammonia, assess for occult cirrhosis).
• Thyroid dysfunction (TSH, free T4).
• An independent neurological or psychiatric cause unrelated to resmetirom.

Do not attribute cognitive symptoms to resmetirom without ruling out these more common alternatives first.

Gaps in the Evidence and Future Research

The current evidence base has real limits that clinicians should acknowledge.

No Dedicated Neurocognitive Endpoints in MAESTRO-NASH

MAESTRO-NASH was powered for histological endpoints, not neuropsychological ones. No formal cognitive battery (ADAS-Cog, MMSE, MoCA, or similar) was administered to participants [6]. The absence of a cognitive signal in adverse-event reporting is reassuring but is not the same as a prospective demonstration of cognitive safety or benefit.

No Long-Term CNS Data Beyond 52 Weeks

The 52-week trial duration is short relative to the timescales over which cognitive disease develops. Resmetirom's long-term cognitive effects, good or bad, remain unknown. Extension studies and real-world pharmacovigilance data will be informative.

No Neuroimaging Data

No published data exist on resmetirom's effect on cerebral blood flow, white matter integrity, or amyloid burden. These would be the most direct ways to measure a drug's impact on brain health over time.

The FDA's 2024 approval requires Gilead Sciences to conduct a post-marketing study examining long-term cardiovascular outcomes [4]. Whether a cognitive substudy is added to that protocol remains to be seen.